In solid tumors, studies have shown that high expression of PD-L2 is associated with shorter disease-free survival (DFS) and overall survival (OS) in lung adenocarcinoma (17), esophageal cancer (18), gastric cancer (19), and hepatocellular carcinoma (20). The gene discussed is PDCD1LG2; the disease is lung adenocarcinoma.